Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas.
SEER
hepatic angiosarcomas
hepatic epithelioid hemangioendotheliomas
hepatic malignant vascular tumors
prognosis
surgery
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
14
09
2021
received:
29
06
2021
accepted:
01
10
2021
pubmed:
2
12
2021
medline:
18
3
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
Malignant vascular tumors (MVTs) are rare and often misdiagnosed due to wide range of clinical presentations, varied histology, and exquisite imagining features. We aim to characterize two different types of MVTs of the liver: hepatic angiosarcomas (HA) and hepatic epithelioid hemangioendotheliomas (HEHE). Data on HA and HEHE between 1975 and 2016 were extracted from the SEER database and analyzed. A total of 366 patients with HA were identified where 64.2% were male and 79% of White race. The median age at diagnosis was 64 ± 16.2 years. Distant metastasis was found in 24% of patients, regional disease in 22.1%, and localized disease in 21.3%. The median overall survival for HA was 2 months. For HEHE, 120 cases were identified, 32.5% were male and 80% of White race. The median age of diagnosis was 51 ± 16.8 years. Distant metastasis was found in 37.5% of patients, regional disease in 27.5%, and localized disease in 20%. The median overall survival was 182 months. Patients' demographics such as race, age, and gender may assist in elucidating distinct subtypes of MVTs. HA is an aggressive tumor despite intervention. Patients with HEHE tumors have significantly better survival compared to patients with HA. Further studies are needed to deepen our knowledge about the histopathology of these tumors, the outcomes of liver transplantation as a therapeutic alternative, and available molecular targets for MVTs.
Sections du résumé
BACKGROUND
Malignant vascular tumors (MVTs) are rare and often misdiagnosed due to wide range of clinical presentations, varied histology, and exquisite imagining features. We aim to characterize two different types of MVTs of the liver: hepatic angiosarcomas (HA) and hepatic epithelioid hemangioendotheliomas (HEHE).
METHODS
Data on HA and HEHE between 1975 and 2016 were extracted from the SEER database and analyzed.
RESULTS
A total of 366 patients with HA were identified where 64.2% were male and 79% of White race. The median age at diagnosis was 64 ± 16.2 years. Distant metastasis was found in 24% of patients, regional disease in 22.1%, and localized disease in 21.3%. The median overall survival for HA was 2 months. For HEHE, 120 cases were identified, 32.5% were male and 80% of White race. The median age of diagnosis was 51 ± 16.8 years. Distant metastasis was found in 37.5% of patients, regional disease in 27.5%, and localized disease in 20%. The median overall survival was 182 months.
CONCLUSION
Patients' demographics such as race, age, and gender may assist in elucidating distinct subtypes of MVTs. HA is an aggressive tumor despite intervention. Patients with HEHE tumors have significantly better survival compared to patients with HA. Further studies are needed to deepen our knowledge about the histopathology of these tumors, the outcomes of liver transplantation as a therapeutic alternative, and available molecular targets for MVTs.
Identifiants
pubmed: 34850580
doi: 10.1002/cam4.4403
pmc: PMC8683533
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8883-8890Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Med. 2021 Dec;10(24):8883-8890
pubmed: 34850580
Curr Treat Options Oncol. 2018 Mar 15;19(4):19
pubmed: 29546487
Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):29-35
pubmed: 31822393
Occup Environ Med. 2017 Oct;74(10):709-716
pubmed: 28490663
Br J Radiol. 2017 Nov;90(1079):20170373
pubmed: 28766950
J Gastroenterol Hepatol. 2014 May;29(5):906-11
pubmed: 24372769
Clin Liver Dis. 2001 Feb;5(1):219-57, viii
pubmed: 11218917
Diagn Pathol. 2014 Jul 01;9:131
pubmed: 24986479
Medicine (Baltimore). 2016 Sep;95(39):e4952
pubmed: 27684838
Eur J Surg Oncol. 2015 Sep;41(9):1137-43
pubmed: 26008857
Sci Transl Med. 2011 Aug 31;3(98):98ra82
pubmed: 21885404
BMJ Case Rep. 2017 Oct 19;2017:
pubmed: 29054942
J Clin Microbiol. 2011 Nov;49(11):4006-12
pubmed: 21918021
J Surg Oncol. 2018 Apr;117(5):886-891
pubmed: 29355969
Radiology. 2002 Mar;222(3):667-73
pubmed: 11867783
Ann Surg Oncol. 2019 Feb;26(2):576-582
pubmed: 30456677
Abdom Radiol (NY). 2019 Apr;44(4):1617-1620
pubmed: 30367214
Clin Res Hepatol Gastroenterol. 2016 Apr;40(2):136-8
pubmed: 26546177
Ann Oncol. 2009 Apr;20(4):780-7
pubmed: 19179547
Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):198-203
pubmed: 29724676
Chest. 2011 Nov;140(5):1312-1318
pubmed: 21546438
Sci Rep. 2019 Dec 3;9(1):18199
pubmed: 31796844
J Surg Oncol. 2014 Apr;109(5):483-6
pubmed: 24284733
Arch Pathol Lab Med. 2018 Feb;142(2):263-267
pubmed: 29372848
J Hepatobiliary Pancreat Surg. 2003;10(3):250-2
pubmed: 14605984
Oncol Rev. 2014 Oct 13;8(2):259
pubmed: 25992243
Int J Surg Case Rep. 2016;28:165-168
pubmed: 27718433
Int J Surg Case Rep. 2018;53:25-28
pubmed: 30366173